Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, New York
- Most recent report
- 10-Q, filed Aug 5, 2026
- Filings on record
- 626 filings
- On EDGAR
- CIK 1802768
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 25
News 8 of 79
- 8-K Quarterly results Aug 5, 2026
- 8-K Shareholder vote results Jun 4, 2026
- 8-K Significant contract May 28, 2026
- 8-K Quarterly results May 6, 2026
- 8-K Current report on a material event Apr 13, 2026
- 8-K Quarterly results Feb 11, 2026
- 8-K Leadership change Dec 22, 2025
- 8-K Current report on a material event Dec 22, 2025
Prospectuses and Registrations 8 of 25
- 424B2 Prospectus supplement for an offering Sep 3, 2025
- FWP Free writing prospectus Sep 3, 2025
- 424B2 Prospectus supplement for an offering Sep 2, 2025
- S-8 Registration statement for an employee plan May 16, 2025
- 424B5 Prospectus supplement for an offering Jun 4, 2024
- FWP Free writing prospectus Jun 3, 2024
- 424B5 Prospectus supplement for an offering Jun 3, 2024
- S-3ASR Automatic shelf registration Jun 3, 2024
Proxies 8 of 19
- DEFA14A Extra proxy material Apr 10, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 10, 2026
- DEFA14A Extra proxy material Apr 11, 2025
- DEFM14A Apr 11, 2025
- DEFA14A Extra proxy material Apr 10, 2025
- DEFA14A Extra proxy material Mar 5, 2025
- PREM14A Feb 13, 2025
- DEFA14A Extra proxy material Jan 17, 2025
Ownership 8 of 430
- 4 Insider reported a trade Aug 19, 2026
- 144 Notice of a proposed sale of restricted stock Aug 18, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Aug 17, 2026
- 4 Insider reported a trade Aug 17, 2026
- 13F-NT Aug 14, 2026
- 144 Notice of a proposed sale of restricted stock Aug 13, 2026
- 144 Notice of a proposed sale of restricted stock Aug 12, 2026
- 144 Notice of a proposed sale of restricted stock Aug 12, 2026
Other 8 of 48
- ARS Annual report sent to shareholders Apr 10, 2026
- POSASR Sep 2, 2025
- ARS Annual report sent to shareholders Apr 11, 2025
- UPLOAD Comment letter from SEC staff Apr 9, 2025
- CORRESP Reply to SEC staff Apr 4, 2025
- UPLOAD Comment letter from SEC staff Mar 28, 2025
- 425 Jan 15, 2025
- ARS Annual report sent to shareholders Apr 25, 2024
Everything here comes from Royalty Pharma plc's own filings on SEC EDGAR. The filing list is rechecked every hour.